All Stories

  1. LIDEB's Useful Decoys (LUDe): A freely available decoy-generation tool. Benchmarking and scope
  2. An update on the novel methods for the discovery of antiseizure and antiepileptogenic medications: where are we in 2024?
  3. Clustering of small molecules: new perspectives and their impact on natural product lead discovery
  4. Clustering of Small Molecules
  5. Compartmental Pharmacokinetic Models
  6. Drug Absorption
  7. Drug Distribution
  8. Drug Excretion
  9. Drug Metabolism
  10. Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro
  11. Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease
  12. LIDeB Tools: A Latin American resource of freely available, open-source cheminformatics apps
  13. iRaPCA and SOMoC: Development and Validation of Web Applications for New Approaches for the Clustering of Small Molecules
  14. Drug Discovery Paradigms: Phenotypic-Based Drug Discovery
  15. Structure-Based Binding Pocket Detection and Druggability Assessment
  16. Free Drug Theory
  17. Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study
  18. Ensemble learning application to discover new trypanothione synthetase inhibitors
  19. Active and Facilitated Transport in Drug Absorption
  20. Biliary Drug Excretion
  21. Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient
  22. Central Nervous System Bioavailability
  23. Cytochrome P450
  24. Drug Absorption
  25. Drug Binding to Plasma Proteins
  26. Drug Binding to Tissue Components
  27. Drug Distribution
  28. Drug Excretion
  29. Drug Metabolism
  30. Drug Metabolism Functionalization (Phase I) Reactions
  31. Drug Metabolism Synthetic (Phase II) Reactions
  32. Enterohepatic Recycling
  33. Enzyme Induction and Drug Metabolism
  34. Factors Impacting on Drug Metabolism
  35. Free Diffusion in Drug Absorption
  36. Intestinal Perfusion Models
  37. One-Compartment Pharmacokinetic Model
  38. Organic Anion Transporters and Organic Anion Transporting Polypeptides
  39. Organic Cation Transporters
  40. Peptide Transporters
  41. Personalized Medicine and Drug Metabolism
  42. Phase 0 and Phase III Transport
  43. Real and Apparent Volumes of Distribution
  44. Renal Drug Excretion
  45. Solute Carrier (SLC) Transporters: An Overview
  46. Total Clearance and Organ Clearance
  47. Transcytosis in Drug Absorption and Distribution
  48. Unbound Brain-to-Plasma Partition Coefficient Determination
  49. pH Partition Theory
  50. pKa Determination
  51. Can drug repurposing strategies be the solution to the COVID-19 crisis?
  52. Positive Predictive Value Surfaces as a Complementary Tool to Assess the Performance of Virtual Screening Methods
  53. In Silico Drug Repositioning for Chagas Disease
  54. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
  55. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease
  56. Quantitative structure–activity relationship models for compounds with anticonvulsant activity
  57. In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach
  58. Application of Machine Learning Approaches to Identify New Anticonvulsant Compounds Active in the 6 Hz Seizure Model
  59. Modern Approaches for the Discovery of Anti-Infectious Drugs for the Treatment of Neglected Diseases
  60. Drug Excretion
  61. Drug Absorption
  62. Drug Distribution
  63. Drug Metabolism
  64. Drug Transporters
  65. The Challenge of Finding New Therapies for Sleeping Sickness
  66. The application of molecular topology for ulcerative colitis drug discovery
  67. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease
  68. Computer-guided drug repurposing: Identification of trypanocidal activity of clofazimine, benidipine and saquinavir
  69. Identification of Levothyroxine Antichagasic Activity through Computer-Aided Drug Repurposing
  70. Application of Computer-Aided Drug Repurposing in the Search of New Cruzipain Inhibitors: Discovery of Amiodarone and Bromocriptine Inhibitory Effects
  71. CNS Drug Development – Lost in Translation?
  72. An Integrated Drug Development Approach Applying Topological Descriptors
  73. Synthesis of 2-Hydrazolyl-4-Thiazolidinones Based on Multicomponent Reactions and Biological Evaluation Against Trypanosoma Cruzi
  74. Prediction of drug intestinal absorption by new linear and non-linear QSPR
  75. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben
  76. Application of descriptors based on Lipinski’s rules in the QSPR study of aqueous solubilities